Duvelisib was the 2nd PI3K inhibitor authorised via the FDA, also dependant on a section III randomized trial.130 The efficacy and protection profile with the drug seem comparable with All those of idelalisib, Otherwise somewhat advantageous. With regards to alternate BTK inhibitors, there are vario